Mood Reactive Disorders among COVID-19 Inpatients: Experience from a Monocentric Cohort.
Coronavirus disease 2019
Depression
Mental health
Mood disorders
SARS-CoV-2
Journal
Medical principles and practice : international journal of the Kuwait University, Health Science Centre
ISSN: 1423-0151
Titre abrégé: Med Princ Pract
Pays: Switzerland
ID NLM: 8901334
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
01
2021
accepted:
13
07
2021
pubmed:
25
11
2021
medline:
25
12
2021
entrez:
24
11
2021
Statut:
ppublish
Résumé
We aimed to investigate the presence and severity of depressive symptoms among coronavirus disease 2019 (COVID-19) inpatients and any possible changes after their discharge. We collected data of patients admitted to the Infectious Disease Unit in Sassari, Italy, for COVID-19, from March 8 to May 8, 2020. The Beck Depression Inventory-II (BDI-II) was performed 1 week after admission (T0) and 1 week after discharge (T1). The cutoff point chosen to define the clinical significance of depressive symptoms was 20 (at least moderate). Forty-eight subjects were included. Mean age was 64.3 ± 17.6 years, and 32 (66.7%) were male. Most frequent comorbidities were cardiovascular diseases (19; 39.6%) and hypertension (17; 35.4%). When performing BDI-II at T0, 21 (43.7%) patients reported depressive symptoms at T0, according to the chosen cutoff point (BDI-II = 20). Eight (16.7%) patients had minimal symptoms. Mild mood disturbance and moderate and severe depressive symptoms were found in 24 (50%), 14 (29.2%), and 2 (4.2%) patients, respectively, at T0. The comparison of the BDI-II questionnaire at T0 with T1 showed a significant improvement in the total score (p < 0.0001), as well as in 4 out of the 5 selected questions of interest (p < 0.05). Univariate analysis showed that kidney failure and the death of a roommate were significantly associated with severity of mood disorders. Mood disturbances and depressive symptoms commonly occur among COVID-19 inpatients. Our results show that COVID-19 inpatients might be at higher risk for developing depressive reactive disorders and could benefit from an early psychological evaluation and strategies improving sleep quality.
Identifiants
pubmed: 34818250
pii: 000518490
doi: 10.1159/000518490
pmc: PMC8739625
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
535-541Informations de copyright
© 2021 The Author(s). Published by S. Karger AG, Basel.
Références
CMAJ. 2020 Apr 14;192(15):E400-E404
pubmed: 32234725
Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2435-2448
pubmed: 33755983
Mult Scler. 2003 Jun;9(3):302-6
pubmed: 12814180
BMC Public Health. 2020 Jun 3;20(1):848
pubmed: 32493337
Soc Anthropol. 2020 Jun 11;:
pubmed: 32836989
J Couns Psychol. 2011 Jul;58(3):410-23
pubmed: 21574694
Eur J Case Rep Intern Med. 2020 Apr 09;7(5):001651
pubmed: 32399450
Int J Infect Dis. 2016 Feb;43:74-76
pubmed: 26751237
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):523-526
pubmed: 33506944
Brain Behav Immun. 2020 Oct;89:594-600
pubmed: 32738287
Brain Behav Immun. 2018 Oct;73:390-402
pubmed: 29885438
Clin Rehabil. 2000 Feb;14(1):50-4
pubmed: 10688344
Nat Rev Immunol. 2019 Nov;19(11):702-715
pubmed: 31289370
PLoS One. 2021 Mar 16;16(3):e0248009
pubmed: 33724987
Psychol Med. 2018 Oct;48(14):2285-2298
pubmed: 29576041
BMJ Open. 2020 Feb 18;10(2):e030371
pubmed: 32075820
Head Neck. 2020 Jul;42(7):1560-1569
pubmed: 32437022
Int J Clin Health Psychol. 2021 Jan-Apr;21(1):100196
pubmed: 32904715
Eur Rev Med Pharmacol Sci. 2020 Jul;24(14):7861-7868
pubmed: 32744714
Psychiatry Res. 2020 Aug;290:113134
pubmed: 32505030
Ann N Y Acad Sci. 2021 Feb;1486(1):90-111
pubmed: 33009668
Brain Behav Immun. 2020 Aug;88:11-16
pubmed: 32416289
J Hosp Infect. 2020 May;105(1):35-42
pubmed: 32059996
Brain Behav Immun. 2019 Jul;79:236-243
pubmed: 30742884